TICKERNOMICS Sign up
Last Update: 2024-03-28 02:11:54
Adaptive Biotechnologies Corp ( ADPT ) https://www.adaptivebiotech.com
2.88USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-65.05%
ADPT
SPY
32.74%
-92.45%
ADPT
SPY
92.93%
ADPT
0.00%
SPY
224.41%
ADPT
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
470.07
318.31
1.92
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-2.55
2.62
1.52
-23.87
0.00
-1.76
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-134.38
48.98
-111.63
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-53.73
-30.88
0.00
Other Earnings and Cash Flow Stats:
Adaptive Biotechnologies Corp ( ADPT ) Net Income TTM ($MM) is -181.73
Adaptive Biotechnologies Corp ( ADPT ) Operating Income TTM ($MM) is -192.77
Adaptive Biotechnologies Corp ( ADPT ) Owners' Earnings Annual ($MM) is -140.51
Adaptive Biotechnologies Corp ( ADPT ) Current Price to Owners' Earnings ratio is -5.06
Adaptive Biotechnologies Corp ( ADPT ) EBITDA TTM ($MM) is -169.38
Adaptive Biotechnologies Corp ( ADPT ) EBITDA Margin is -111.63%
Capital Allocation:
Adaptive Biotechnologies Corp ( ADPT ) has paid 0.00 dividends per share and bought back -2.566354 million shares in the past 12 months
Adaptive Biotechnologies Corp ( ADPT ) has reduced its debt by 111.932 million USD in the last 12 months
Capital Structure:
Adaptive Biotechnologies Corp ( ADPT ) Interest-bearing Debt ($MM) as of last quarter is 130
Adaptive Biotechnologies Corp ( ADPT ) Annual Working Capital Investments ($MM) are 1
Adaptive Biotechnologies Corp ( ADPT ) Book Value ($MM) as of last quarter is 308
Adaptive Biotechnologies Corp ( ADPT ) Debt/Capital as of last quarter is 42%
Other Balance Sheet Stats:
Adaptive Biotechnologies Corp ( ADPT ) has 65 million in cash on hand as of last quarter
Adaptive Biotechnologies Corp ( ADPT ) has 88 million of liabilities due within 12 months, and long term debt 133 as of last quarter
Adaptive Biotechnologies Corp ( ADPT ) has 145 common shares outstanding as of last quarter
Adaptive Biotechnologies Corp ( ADPT ) has 0 million USD of preferred stock value
Academic Scores:
Adaptive Biotechnologies Corp ( ADPT ) Altman Z-Score is -1.83 as of last quarter
Adaptive Biotechnologies Corp ( ADPT ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Adaptive Biotechnologies Corp ( ADPT ) largest shareholder is owning shares at 0.00 ($MM) value
Tycho Peterson(an insider) Sold 15456 shares of Adaptive Biotechnologies Corp ( ADPT ) for the amount of $53168.64 on 2024-03-05
1.80% of Adaptive Biotechnologies Corp ( ADPT ) is held by insiders, and 91.84% is held by institutions
Adaptive Biotechnologies Corp ( ADPT ) went public on 2019-06-27
Other Adaptive Biotechnologies Corp ( ADPT ) financial metrics:
FCF:-191.94
Unlevered Free Cash Flow:-128.29
EPS:-1.39
Operating Margin:-134.38
Gross Profit Margin:48.98
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-65.24
Beta:0.00
Buffet's Owners Earnings:-140.51
Price to Owner's Earnings:-5.06
About Adaptive Biotechnologies Corp ( ADPT ) :
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer and autoimmune disorders. It offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.